Journal of Molecular Oncology Research

About The Journal Open Access

Journal of Molecular Oncology Research

Molecular oncology refers to the process of tumor formation within the molecular level and its effects along with various therapeutic methods in the cancer treatment.

The Journal of Molecular Oncology Research (JMOR) is an international, peer reviewed journal that encourages high-quality original research, systematic reviews, meta-analyses and technology reports, perspectives on all disciplines and therapeutic areas within the specialty.

Aims and Scope

The journal aims to further research on broad spectrum of discoveries related to therapeutic advances in cancer treatment, molecular phenotypes, tumor diagnosis, cancer genetics, epigenetics, genomic instability, tumor immunology, chemotherapy, radiotherapy and surgery, etc. The principal criterion for publication is to establish a novel concept of clinical significance in diagnosis, prognosis and prevention strategies for cancer patients.

This multidisciplinary open access journal ensures wide spread dissemination of research work as original Research Articles, Review Article, Case Reports, Short Communication, Opinion Articles and Letter to Editor.

The journal prioritizes molecular analysis that provides novel mechanistic insight into pathways and processes linked to cancer risk, development, and/or progression. The journal emphasizes on all cancer-associated pathways (including cell-cycle regulation; cell death; chromatin regulation; DNA damage and repair; gene and RNA regulation; genomics; oncogenes and tumor suppressors; and signal transduction). For full consideration, primary research submissions must provide significant novel insight into existing pathway functions or address new hypotheses associated with cancer-relevant biologic questions.

The Journal is using Editor Manager System for easy online submission and tracking of the manuscript. To be acceptable for publication, an article should be positively considered by two individual reviewers followed by the Editor’s consent.

Authors are requested to submit mansucript at Online Mnaucript Submission System or send  as an email attachment to [email protected]/[email protected]

Please submit your manuscript to
[email protected]

Just Published Articles View More

Review Article October 30, 2018

P.74-86

J Mol Oncol Res: 2(3): 74-86

Incivility of passive immunity

Gerald M. Higa*, Katie Murto

DOI:10.35841/molecular-oncology.2.3.74-86

Research Article October 30, 2018

P.68-73

J Mol Oncol Res: 2(3): 68-73

Efficacy and safety of pemetrexed and cisplatin chemotherapy as first line in advanced stage of lung adenocarcinoma.

Kartikeya Jain, Ajay Bapna*, Naresh Somani, Lalit Mohan Sharma, Pawan Aggarwal

DOI:10.35841/molecular-oncology.2.3.68-73

Review Paper October 17, 2018

P.63-67

J Mol Oncol Res: 2(3): 63-67

A key receptor in apoptosis: Toll-like receptor 3 (TLR3).

Asuman Deveci Ozkan, Humeyra Nur Kaleli and Suleyman Kaleli

DOI:10.35841/molecular-oncology.2.3.63-67

Review Article October 01, 2018

P.58-62

J Mol Oncol Res: 2(3): 58-62

Developments in the area of bladder cancer genomics and its importance in the treatment selection

Jyoti Sharma, Barnali Deb, Prashant Kumar*

DOI:10.35841/molecular-oncology.2.3.58-62

Research Article October 01, 2018

P.48-57

J Mol Oncol Res: 2(3): 48-57

SCCAg mRNA expression predicts early relapse in histopathologically negative lymphnodes of oral squamous cell carcinoma patients.

Trupti Trivedi*, Rajan Tankshali, Dhaval Jetly, Nandita Ghosh, Prabhudas Patel

DOI:10.35841/molecular-oncology.2.3.48-57

Case Report October 01, 2018

P.45-47

J Mol Oncol Res: 2(3): 45-47

Growing teratoma syndrome presented as a left forearm mass: A case report.

Ioannis Litos*, Eleni Maragkouli, Vassilis Papadopoulos, Konstantinos Tsapakidis, Konstantina Papacharalambous, Ioannis Samaras, Eleni Sogka, Athina Isaakidou, Alexandra Markou, George Papatsimpas

DOI:10.35841/molecular-oncology.2.3.45-47